Biotechpharma plans to develop a second-generation express system for the production of IgG1 monoclonal therapeutic antibodies. The second-generation express system will have at least 2 times higher productivity than the first generation of express systems currently available on the market. During the project, applied cell technology research will be carried out to optimise the current production processes of recombinant monoclonal IgG1 antibodies and to increase their productivity several times. The project will examine the processes of gene transfer, cell cloning, and the influence of cell culture conditions (in these processes) on the final results of the processes. In the context of R & D activities, their individual phases will be aimed at researching and developing the individual technologies described in the project. The final stage of experimental development will enable all intermediate process innovations to be developed and tested under realistic conditions for the production and testing of the IgG1 monoclonal antibody test batch. This will enable Biotechpharma to expand its product and service portfolio, successfully commercialise its R & D results and become a globally competitive biopharmaceutical company.